Navigation Links
Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting
Date:12/9/2007

- MGCD0103 Continues to Demonstrate Single-Agent Activity - 38% Response Rate, 43% Disease Control Rate and 86% Tumor Reduction Rate in Heavily-Pretreated Patients with Relapsed or Refractory Hodgkin Lymphoma

in 110mg Cohort - 67% Tumor Reduction Rate in Relapsed or Refractory Non-Hodgkin Lymphoma, Including an 18% Response Rate in Evaluable Diffuse Large B- cell Patients

ATLANTA, Dec. 9 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM) and MethylGene Inc. (TSX: MYG) today announced data from two ongoing Phase 2 studies with MGCD0103, the Companies' novel, isotype-selective histone deacetylase (HDAC) inhibitor, as a single-agent in the treatment of Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Data from these studies were presented today at the 49th Annual Meeting and Exposition of the American Society of Hematology (ASH).

"These exploratory Phase 2 trials show meaningful activity of MGCD0103 in patients with differing types of lymphomas," said Patrick J. Mahaffy, president and chief executive officer of Pharmion. "This is important not only for the continuing development of MGCD0103 but also because it provides further evidence for the role of epigenetic therapies in the treatment of hematologic malignancies."

"Data from these most recent trials continue to demonstrate the single- agent potential for MGCD0103 in a patient population that currently has few effective therapeutic options," said Donald F. Corcoran, president and chief executive officer of MethylGene. "With our partners, we will continue to evaluate our current and near-term MGCD0103 clinical trials during 2008 with the goal to develop a potential registrational pathway."

Isotype Selective HDAC Inhibitor MGCD0103 Decreases Serum TARC Concentrations and Produces Clinical Responses in Heavily Pretreated Patients with Relapsed Classical Hodgkin lymphoma (HL), Abstract #2566 (Trial 010)

To date, 33 patients
'/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Pharmion and GPC Biotech Announce Results of Overall Survival Analysis From the Satraplatin Pivotal Phase 3 Trial
2. Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting
3. Virginia Tech Report Has National Importance
4. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
5. GAO Report Confirms: Medicare Underpays for Anesthesia Services; Nurse Anesthetists Assure Seniors Access to Safe Anesthesia Care
6. Haemacure Reports Third Quarter 2007 Results
7. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
8. Biotech Finishes on a High in August, Burrill Report Says
9. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
10. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
11. MDS Reports Third Quarter 2007 Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)...Newswire/ -- The American Medical Association (AMA...Court for the Southern District of New York has gr...osed $350 million settlement that would resolve a ..., The action brought by the AMA, Medical Societ...cal Association, along with several other plaintif...
(Date:12/3/2009)...nimally invasive procedures, study finds , ...lly fatal blood clots after surgery are a much gre...ish study finds. , "What is most striking is th...much longer than people have thought," said Dr. Ja...ity of Oxford and a leader of the team reporting t...
(Date:12/3/2009)...ing of diabetes, cardiovascular disease, researche...ews) -- Pregnant women who develop gestational glu...isk for metabolic syndrome three months after they...ucose intolerance is less severe than gestational ... factors (including high blood pressure, obesity a...
(Date:12/3/2009)...hether they cause brain cancer, , , THU...nes cause brain cancer has been a subject of ongoi...nce suggesting that they don,t. , A 30-year exa...inavia found no substantial change in prevalence e...ing to the report in the Dec. 3 online edition of ...
(Date:12/3/2009)...The day has come. Eight months in the planning, de...re RN organizations will gather in Phoenix Monday,... 150,000-member National Nurses United, the larges...story. ,, AFL-CIO President Richard Trumka will... will chart a course for the building of a more po...
Breaking Medicine News(10 mins):Health News:Settlement in AMA Lawsuit against UnitedHealth Gets Preliminary Approval from Federal Court 2Health News:Blood Clot Threat After Surgery Worse Than Thought 2Health News:Blood Clot Threat After Surgery Worse Than Thought 3Health News:Blood Sugar Intolerance May Predict Postpartum Ills 2Health News:No Increase in Brain Tumors Seen From Cell Phones 2Health News:No Increase in Brain Tumors Seen From Cell Phones 3Health News:RN SuperUnion Founding Convention Opens Monday 2
..., 2009 -- The device looks deceptively simple a p...ket with a spigot but Vinka Craver believes it ca...nt professor of civil and environmental engineerin... becomes safe to drink., "More than one billion ...
...National Safety Council will host a National Poiso... National Poison Prevention Week Council, Tuesday,... Club in Washington, D.C. The event will feature a...duation. Other speakers will include: , , , ,...
...etary of Labor Hilda L. Solis today announced the ...king (ANPRM) for occupational exposure to food fla...ill facilitate the Labor Department,s Occupational...y fatal lung disease associated with such an expos...
... Medical, Inc., manufacturer of the CryoSpray Abla...f its newly redesigned Web site ( www.CSAmedical.c.../prnh/20080721/NEM114LOGO ) , , The Web site fea...e and destroy unwanted tissue in the body. The upd...
...ntertechPira,s 2009 Applications of High-Power Sem...er 15 - 17, 2009 in San Diego, CA , ... Applications of High-Power Semiconductor Lasers (...PSL 2009 will be divided into sectors reflecting i...
..., 2009 A new study published in Epilepsia finds... as high in people with epilepsy compared to the g...al minorities have seven times the odds of depress...ng mental healthcare services. , Data from the 20...
Other Medicine News:Health News:Engineer helps poor in developing nations purify drinking water 2Health News:NSC Hosts National Poison Prevention Week News Conference, Tuesday, March 17 2Health News:U.S. Secretary of Labor Hilda L. Solis takes action to prevent workers' exposure to food flavorings chemical 2Health News:CSA Medical, Inc. Announces Launch of New Web Site for Spray Cryotherapy 2Health News:Call for Presentations: Applications of High-Power Semiconductor Lasers Conference & Exhibit 2Health News:Depression twice as likely in seizure sufferers 2
(Date:12/3/2009)... , WALTHAM, Mass., Dec. 3 Dec...ch and advisory firms focusing on pharmaceutical a...abetes drug market in Brazil will grow from $417 m...ted 15 percent annual growth rate is attributed to...increased use of new generation antidiabetics such...
(Date:12/3/2009)...SAN DIEGO, Dec. 3 Amira Pharmace...a from a Phase 1 clinical study of AM461, the Comp...(also known as CRTH2) receptor. ,, The interi...rmacodynamic (PD) effect can be achieved with AM46...strates a good safety profile. AM461 is a back-up...
(Date:12/3/2009)..., NANJING, China, Dec. 3 /PRNewswire-Asia/ ..."Company") (NYSE: SCR ), a leading pharmaceutica...turing, and marketing of branded,generic and propr...at China,s,State Food and Drug Administration ("SF...nto quality issues regarding human use rabies vacc...
Breaking Medicine Technology:Brazil's Type 2 Diabetes Drug Market Will Grow to $834 Million by 2013 2Brazil's Type 2 Diabetes Drug Market Will Grow to $834 Million by 2013 3Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amira's Lead DP2 Antagonist, AM211 2Simcere Pharmaceutical Group Provides Update on Jiangsu Yanshen 2Simcere Pharmaceutical Group Provides Update on Jiangsu Yanshen 3Scientists demonstrate importance of niche differences in biodiversity 9554 1Scientists demonstrate importance of niche differences in biodiversity 9554 2Erik Estrada Accepts Honorary Appointment from Project Lifesaver International 54365 1Erik Estrada Accepts Honorary Appointment from Project Lifesaver International 54365 2Sisters of Charity Health System Welcomes Shannon Fogarty Jerse as Deputy General Counsel 54361 1Sisters of Charity Health System Welcomes Shannon Fogarty Jerse as Deputy General Counsel 54361 2Sisters of Charity Health System Welcomes Shannon Fogarty Jerse as Deputy General Counsel 54361 3
...n who adhere to a traditional Mediterranean diet -...le grains and fish -- are at a lower risk for stro...y published this week in Circulation: Journal... . , , The research, led by Simmons College Nut...se diets most closely resembled the Mediterranean ...
...ruary 17 Sanofi Pasteur, the,vaccines division of...NY),announced today that it is sponsoring a phase ... difficile, which is among the most common causes ... America. , The trial currently conducted in t...efficacy of sanofi pasteur,s C. difficile candidat...
Other Medicine Technology:Risk of Stroke, Heart Disease in Women Lowered by Mediterranean Diet 2Risk of Stroke, Heart Disease in Women Lowered by Mediterranean Diet 3Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile 2Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile 3Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile 4Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile 5
5.5mm Trephine Handle
10.0mm Calibrated Trephine Handle
8.25mm Calibrated Trephine Handle
6.5mm Calibrated Trephine Handle
Medicine Products: